Poplar Therapeutics Raises $45 Million to Advance Anti-IgE Therapy
Poplar Therapeutics, based in Cambridge, Massachusetts, has successfully closed a $45 million Series A extension funding round. The company, founded by Vicki Eatwell, is dedicated to developing next-generation anti-IgE medicines aimed at helping patients live free from the fear of IgE-mediated conditions.
Funding Details
The Series A extension was led by Janus Henderson Investors, with participation from RA Capital, which joins as a new investor. Existing investors SR One, Vida Ventures, and ArrowMark Partners also contributed to the round. This infusion of capital is earmarked to propel the clinical development of Poplar Therapeutics' lead asset, PHB-050.
Focus on PHB-050
PHB-050 is currently undergoing a Phase 1 clinical trial aimed at treating food allergies. The trial is set to provide crucial data on the safety and pharmacokinetics of the drug, as well as its ability to rapidly decrease circulating IgE levels. This data will be instrumental in guiding the next phases of clinical development.
The therapy is designed with a triple-action mechanism that seeks to block IgE from binding to mast cells, reduce circulating IgE, and inhibit its production. This approach targets not just food allergies but also other atopic diseases such as asthma and atopic dermatitis.
Executive Insights
Chip Baird, Poplar Therapeutics' CEO, is steering the company through this pivotal phase. Speaking about the funding, Daniel Lyons, PhD, CFA, Portfolio Manager and Research Analyst at Janus Henderson, commented: "Poplar Therapeutics is advancing a differentiated approach that has the potential to redefine how IgE-mediated diseases are treated."
Strategic Use of Funds
The newly acquired funds will primarily support the ongoing clinical trials of PHB-050. The company aims to validate its novel mechanism through upcoming Phase 1 data, which is expected to be a significant milestone in their development pipeline.
Addressing a Critical Need
Despite existing therapies like omalizumab (Xolair), millions of patients with high IgE levels remain underserved. Poplar Therapeutics is committed to addressing this gap, with over seven million patients experiencing atopic conditions and about three million not responding to current standard treatments.
This Series A extension marks a significant step for Poplar Therapeutics as they continue to innovate in the immunology space, working towards improving outcomes for those living with IgE-mediated diseases.